Dean, School of Basic Medical Sciences, University of
Benin, Prof. Isaiah Ibeh, on Tuesday announced the development of a new
drug that can cure HIV and AIDS.
Ibeh told the News Agency of Nigeria in Benin, the Edo State capital, that the herbal drug had undergone “a series of successful tests.”
The University Public Relations Officer, Harrison
Osarenren, confirmed the story to our correspondent in a telephone
interview on Tuesday.
He said the professor had found the solution. “The
professor just developed a drug that can cure HIV/AIDS and it has been
tested. He has solution to AIDS.”
Ibeh told NAN, “We are at the threshold of making
history, in the sense that we seem to have with us something that will
permanently take care of what over time seems to have defied all
solutions.
“We are talking about the latest discovery of an oral
drug made from plants extraction in Nigeria for the possible cure for
the pandemic, HIV and AIDS virus.’’
According to him, research on the project was started
in 2010 and culminated in the development of
“Deconcotion X (DX)–Liquid
or Bioclean 11 for the cure of HIV and AIDS.”
Ibeh added, “The existing retroviral drugs are
intervention drugs for the management of AIDS but our new discovery is a
possible cure. We have tried to look at the product first; its
toxicological analysis and discovered that it has a large safety margin.
“This means that if animals or human beings are exposed to it, they will not suffer any serious harm at all from the exposure.
“It also helped us to know the quantity we can
conveniently give to animals and will feel secure that nothing untoward
will happen.
“We have also done the bacteriological analysis on
it, after which we looked at its effect on the virus and the result was
quite revealing and refreshing.’’
Ibeh also said that the drug had been exposed to
series of medical examination both in Nigeria and in the USA. He added
that the drug had performed well on patients with the HIV virus and had
shown evidence of total restoration of damaged tissues.
He said, “The result showed an increase in the body weight of the individual administered with DX.
“The body weight was statistically significant when
compared with the control group.’’ He said that further tests were being
conducted to determine “at what point will a patient become negative
after being administered the drug?”
He said, “This verification is necessary because it
is what is used to measure whether infection is still there or not. So
we need to know the siro-convention time.
“But preliminary results showed that of the five latest patients orally administered with the drugs, our findings is that up to seven months three of them were siro negative while two were still faintly positive.’’ Ibeh appealed for support from the Federal Government and relevant bodies to assist the university with relevant equipment to sustain the research.
Punch
No comments:
Post a Comment